Health Canada Approves Aflivu™ by Apotex
Apotex Inc., a prominent global health company based in Canada, recently received validation from Health Canada for Aflivu™ (aflibercept). This biosimilar is designed to address several significant retinal conditions, including neovascular (wet) age-related macular degeneration, macular edema resulting from retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization.
A Key Milestone for Apotex
This approval is more than just a regulatory success; it represents the introduction of Apotex’s first ophthalmic biosimilar and its fourth biosimilar product since 2016. This move underscores the company’s dedication to expanding its range of biologics and fulfilling its Journey of Health strategy, aimed at enhancing health solutions for patients.
Affordable Treatment Options
Raymond Shelley, President of Apotex Canada, expressed enthusiasm about the launch, stating, "With Aflivu, we're expanding affordable treatment options for Canadians affected by retinal diseases." This statement highlights the company's ongoing commitment to providing innovative and patient-centered healthcare solutions that focus on accessibility.
Impact on Ophthalmic Care
Healthcare professionals are optimistic about the approval of Aflivu™. Dr. Bernard R. Hurley, an ophthalmology expert and Assistant Professor at the University of Ottawa Eye Institute, remarked that the advancement of biosimilars could significantly transform ophthalmic care. "Biosimilars, supported by clinicians, regulators, and manufacturers, have the potential to transform the treatment landscape for retinal diseases," he said, emphasizing their role in maintaining vision and offering cost-effective solutions for the community.
Empowering Physicians
Dr. Ghassan Cordahi, also a clinical expert in this field, added, "In clinical practice, having access to a broader range of therapeutic options can empower physicians to tailor care to individual patients' needs." He acknowledged Aflibercept's critical role in managing retinal diseases and highlighted how Aflivu gives a more affordable yet quality alternative to existing treatments.
Aflivu™ Joins a Growing Portfolio
Aflivu™ is now part of Apotex’s expanding biosimilar lineup, which already includes notable products like Grastofil® (filgrastim), Lapelga® (pegfilgrastim), and Bambevi® (bevacizumab). This strategic addition strengthens Apotex’s position in the market and commitment to provide innovative treatments that enhance patient care.
About Apotex
Apotex is dedicated to improving access to essential health products worldwide. The company operates on a global scale and offers a diverse catalog of generic, biosimilar, and branded pharmaceutical products tailored to meet the needs of millions. With its headquarters in Toronto and regional offices spanning the Americas, including the United States, Mexico, and India, Apotex has established itself as the leading Canadian-based pharmaceutical enterprise.
The company continually seeks to innovate and expand its offerings to serve as a trusted health partner across international pharmaceutical markets.
Frequently Asked Questions
What is Aflivu™?
Aflivu™ is a biosimilar to Eylea® developed by Apotex, intended for treating various retinal conditions.
What conditions does Aflivu™ treat?
Aflivu™ is indicated for neovascular age-related macular degeneration, macular edema due to retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization.
Why is the approval of Aflivu™ significant?
This approval marks a landmark moment for Apotex, enhancing their biosimilar portfolio while promoting affordable treatment options for patients.
How does Aflivu™ benefit patients?
Aflivu™ offers a more cost-effective treatment alternative, allowing for better access and tailored care for individuals dealing with retinal diseases.
What does Apotex aim for with its products?
Apotex strives to deliver innovative, affordable healthcare solutions, bringing quality medicines to patients around the world.
